Specialty Pipeline Update
|
|
- Rudolf Carter
- 6 years ago
- Views:
Transcription
1 Specialty Pipeline Update D Drug Insights > March 2016 New drug information Odefsey (emtricitabine, tenofovir alafenamide, rilpivirine): The Food and Drug Administration (FDA) approved Gilead s combination HIV treatment. Odefsey is similar to Complera, but contains a new tenofovir salt. Idelvion (coagulation Factor IX [recombinant], albumin fusion protein): The FDA approved CSL Behring s Idelvion for the treatment of hemophilia B. This is a long-acting drug that can be administered once every two weeks in appropriate patients. Kovaltry (octocog alfa): Bayer received FDA approval for their hemophilia factor replacement. Kovaltry is approved for the treatment of hemophilia A in children and adults. Evomela (captisol-enabled melphalan): The FDA approved Spectrum s Evomela for two indications. The first indication is for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation (ASCT) in patients with multiple myeloma (MM). This is the first drug to receive this indication. The second indication is for the palliative treatment of patients with MM for whom oral therapy is not appropriate. New indications Ibrance (palbociclib): Pfizer received approval from the FDA for an expanded indication of Ibrance in the treatment of metastatic breast cancer. The new indication is for use in combination with fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in women with disease progression following endocrine therapy. Afinitor (everolimus): The FDA approved Novartis Afinitor for treating inoperable, locally advanced or metastatic neuroendocrine tumors of gastrointestinal or lung origin. Gazyva (obinutuzumab): Genentech received FDA approval for the use of Gazyva in combination with bendamustine followed by obinutuzumab alone for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximabcontaining regimen. Xalkori (crizotinib): The FDA approved Pfizer s Xalkori for patients with the ROS-1 gene mutation. This mutation comprises about 1 percent of U.S. patients with non small cell lung cancer. Xeljanz (tofacitinib): The FDA approved Pfizer s extended-release, once-daily formulation of Xeljanz for the treatment of rheumatoid arthritis. While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.
2 Specialty Pipeline > March 2016 Page 2 March news PTC Therapeutics, Inc. announced that it received yesterday evening a Refuse to File letter from the FDA regarding PTC s New Drug Application (NDA) for Translarna (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (nmdmd). The FDA states in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. PTC first learned of the Refuse to File decision via this letter and is reviewing its content to determine the appropriate next steps. 1 Gilead Sciences has stopped six clinical trials using its drug idelalisib (Zydelig ) in combination with other cancer drugs on account of a higher rate of serious adverse events, including death, the US Food and Drug Administration (FDA) said. The announcement follows the recent decision by European Union (EU) regulators to review idelalisib in response to an increased rate of serious adverse events such as death in three clinical trials that combined the Gilead Sciences drug with other cancer drugs. 2
3 Specialty Pipeline > March 2016 Page 3 Specialty new product approvals in the past twelve months Generic name Brand name Manufacturer Indication(s) Route of administration Date approved* emtricitabine/tenofovir Odefsey Gilead HIV Oral March 2016 alafenamide/rilpivirine coagulation factor IX Idelvion CSL Behring Hemophilia B March 2016 octocog alfa Kovaltry Bayer Hemophilia A March 2016 tofacitinib Xeljanz XR Pfizer Rheumatoid arthritis Oral February 2016 grazoprevir/elbasvir Zepatier Merck Hepatitis C (genotypes 1 and 4) selexipag Uptravi Actelion Pulmonary arterial hypertension von Willebrand factor, recombinant Vonvendi Baxalta von Willebrand disease sebelipase alfa Kanuma Alexion/Synageva Enzyme replacement therapy asfotase alfa Strensiq Alexion Enzyme replacement therapy Subcutaneous Factor VIII, recombinant, pegylated Adynovate Baxalta Hemophilia A Oral January 2016 Oral November 2015 November 2015 mepolizumab Nucala GlaxoSmithKline Severe eosinophilic asthma Subcutaneous November 2015 elvitegravir/cobicistat/ Genvoya Gilead HIV Oral November 2015 emtricitabine/tenofovir alafenamide Factor X concentrate Coagadex BioPorducts Laboratory Factor X deficiency October 2015 uridine triacetate Xuriden Wellstat Therapeutics Hereditary orotic aciduria Oral October 2015 Factor VIII, recombinant Nuwiq Octapharma Hemophilia A September 2015 uridine triacetate Xuriden Wellstat Therapeutics Hereditary orotic aciduria Oral September 2015 dichlorphenamide Keveyis Taro Primary hyperkalemic Oral August 2015 and hypokalemic periodic paralysis. evolocumab Repatha Amgen High cholesterol Subcutaneous August 2015 daclatasvir Daklinza BMS Hepatitis C (genotype 3) Oral July 2015 ombitasvir, paritaprevir, Technivie AbbVie Hepatitis C (genotype 4) Oral July 2015 ritonavir with ribavirin alirocumab Praluent Sanofi-Genzyme High cholesterol Subcutaneous July 2015 lumacaftor/ivacaftor Orkambi Vertex Cystic fibrosis Oral July 2015 coagulation factor IX (recombinant) Ixinity Emergent BioSolutions Hemophilia B May 2015 glatiramer Glatopa Sandoz Multiple sclerosis Subcutaneous April 2015 deferasirox Jadenu Novartis Chronic iron overload Oral April 2015 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product s manufacturer.
4 Specialty Pipeline > March 2016 Page 4 New indications for approved specialty products Generic name Brand name Manufacturer New indication Date approved* ledipasvir/sofosbuvir Harvoni Gilead For the treatment of liver transplant recipients February 2016 with genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis, and for genotype 1-infected patients with decompensated cirrhosis daclatasvir Daklinza Bristol-Myers Squibb For use in combination with Sovaldi February 2016 (sofosbuvir) for the treatment of chronic hepatitis C virus (HCV) in patients co-infected with HIV and for HCV patients with advanced cirrhosis, including decompensated cirrhosis and patients with post-liver transplant recurrence of HCV genotype 1 infection onabotulinumtoxina Botox Allergan For the treatment of adults with lower limb January 2016 spasticity secukinumab Cosentyx Novartis For the treatment of adult patients with active January 2016 ankylosing spondylitis and active psoriatic arthritis ledipasvir/sofosbuvir Harvoni Gilead For use in patients with genotype 4, 5 and November chronic HCV infection and in patients co infected with HIV ambrisentan Letairis Gilead For use in combination with tadalafil for the October 2015 treatment of pulmonary arterial hypertension adalimumab Humira AbbVie For the treatment of moderate to severe September 2015 hidradenitis suppurativa cysteamine Procysbi Raptor Pharmaceuticals Pediatric nephropathic cystinosis in patients August years old abobotulinumtoxina Dysport Ipsen Treatment of upper limb spasticity in adults July 2015 sirolimus Rapamune Pfizer To treat lymphangioleiomyomatosis May 2015 aflibercept Eylea Regeneron To treat diabetic retinopathy April 2015 onabotulinumtoxina Botox Allergan Treatment of upper limb spasticity in adults April 2015 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product s manufacturer.
5 Specialty Pipeline > March 2016 Page 5 Oncology product approvals in the past twelve months Generic name Brand name Manufacturer Indication(s) captisol-enabled melphalan Evomela Spectrum For use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation (ASCT) in patients with multiple myeloma (MM) and for the palliative treatment of patients with MM for whom oral therapy is not appropriate Route of administration Date approved* March 2016 alectinib Alecensa Genentech Non-small cell lung cancer Oral elotuzumab Empliciti Bristol-Myers Squibb/ AbbVie Multiple myeloma bendamustine Bendeka Teva Chronic lymphocytic leukemia and indolent B-cell non-hodgkin lymphoma necitumumab Portrazza Lilly Non-small cell lung cancer November 2015 ixazomib Ninlaro Millennium Multiple myeloma Oral November 2015 Pharmaceuticals/ Takeda daratumumab Darzalex Janssen Multiple myeloma November 2015 osimertinib Tagrisso AstraZeneca Non-small cell lung cancer Oral November 2015 irinotecan liposome Onivyde Merrimack Pharmaceuticals Pancreatic cancer November 2015 trabectedin Yondelis Janssen Soft tissue sarcoma November 2015 cobimetinib Cotellic Genentech Metastatic melanoma Oral November 2015 talimogene Imlygic Amgen Metastatic melanoma Injection October 2015 laherparepvec trifluridine/tipiracil Lonsurf Otsuka Colorectal cancer Oral September 2015 gefitinib Iressa AstraZeneca Non-small cell lung cancer Oral July 2015 sonidegib Odomzo Novartis Basal cell carcinoma Oral July 2015 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product s manufacturer.
6 Specialty Pipeline > March 2016 Page 6 New indications for approved oncology drugs Generic name Brand name Manufacturer New indication Date approved* crizotinib Xalkori Pfizer For patients with the ROS-1 gene mutation March 2016 obinutuzumab Gazyva Genentech For use in combination with bendamustine followed by March 2016 obinutuzumab alone for the treatment of patients with follicular lymphoma everolimus Afinitor Novartis For treating inoperable, locally advanced or metastatic March 2016 neuroendocrine tumors palbociclib Ibrance Pfizer For use in combination with fulvestrant for the treatment March 2016 of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer nivolumab Opdivo Bristol-Myers Squibb To be used in combination with Yervoy as a treatment January 2016 for patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma eribulin mesylate Halaven Eisai For the second-line treatment of liposarcoma January 2016 pembrolizumab Keytruda Merck First-line treatment for unresectable or metastatic melanoma and as a treatment for patients with ipilimumab (Yervoy )-refractory melanoma nivolumab Opdivo Bristol-Myers Squibb For the treatment of BRAF V600 wild-type melanoma ipilimumab Yervoy Bristol-Myers Squibb Adjuvant therapy for patients with stage III melanoma November 2015 nivolumab Opdivo Bristol-Myers Squibb To be used in combination with Yervoy (ipilimumab) for the treatment of patients with unresectable or metastatic melanoma and for the treatment of patients with metastatic nonsquamous, non-small-cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy brentuximab vedotin Adcetris Seattle Genetics To treat patients at high risk of relapse immediately after an autologous hematopoietic stem cell transplant (HSCT) to help prevent progression of the disease October 2015 August 2015 carfilzomib Kyprolis Onyx/Amgen To be used in combination with lenalidomide and July 2015 dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy ramucirumab Cyramza Eli Lilly For use as a second-line treatment option for metastatic colorectal cancer April 2015 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product s manufacturer.
7 Specialty Pipeline > March 2016 Page 7 Pipeline watch Generic name Brand name Manufacturer Indication(s) Route of administration ixekizumab N/A Lilly Plaque psoriasis Subcutaneous pegfilgrastim N/A Apotex Biosimilar to Neulasta filgrastim Grastofil Apotex Biosimilar to Neupogen reslizumab Cinqair Teva Severe eosinophilic asthma Subcutaneous / intravenous daclizumab high-yield process Zinbryta Biogen/AbbVie Multiple sclerosis Subcutaneous defibrotide N/A Jazz Pharmaceuticals hepatic veno-occlusive disease infliximab Remsima Celltrion/Pfizer Biosimilar to Remicade; seeking all indications emtricitabine/tenofovir alafenamide Anticipated FDA decision date* 1st half st half st half Q2016 March April 2016 March 2016 April 2016 N/A Gilead HIV Oral April 2016 octreotide Mycapssa Chiasma Acromegaly Oral April 2016 recombinant factor VIII single chain, rfviii- SingleChain N/A CSL Behring Hemophilia A May 2016 eteplirsen N/A Sarepta Therapeutics Duchenne muscular dystrophy May 2016 obeticholic acid N/A Intercept Primary biliary cirrhosis Oral May 2016 etanercept N/A Sandoz Biosimilar to Enbrel Subcutaneous June 2016 rociletinib N/A Clovis Oncology/ Non-small cell lung cancer Oral June 2016 Celgene sofosbuvir/velpatasvir N/A Gilead Hepatitis C (all genotypes) Oral June 2016 venetoclax N/A Roche/AbbVie Chronic lymphocytic leukemia Oral June 2016 *Expected launch dates are predictions made by Prime Therapeutics based on industry information.
8 Specialty Pipeline > March 2016 Page 8 Watch list Criteria for inclusion on the Watch List include: Drug is submitted to the FDA and is anticipated to have material impact to trend and/or material impact to preferred product strategies (medical or pharmacy). Brand (generic)/ manufacturer eteplirsen/sarepta Therapeutics obeticholic acid Proposed indication/ route of administration Duchenne s muscular dystrophy (IV) Primary biliary cirrhosis (PBC); off-label use for non-alcoholic steatohepatitis (NASH) Anticipated approval (PDUFA date) Similar products (by indication) Spend* Net new impact to PMPM* pharmacy benefit 5/26/2016 None $ none $ 5/29/2016 ursodiol $ $$ (PBC); $$$$ (NASH) $ $$ (PBC); $$$$ (NASH) *Notations: $ < $0.08 per member per month (PMPM), $$ = $0.08 $0.39 PMPM, $$$ = $0.40 $2.00 PMPM, $$$$ > $2.01 PMPM Net new impact to PMPM* medical benefit None References 1 tok=3rkmmjwwff9wsronvqjneu%2fhmjteu5z17ekkwqe0lmi%2f0er3fovrpufgji4armbmnq%2btfawtg5toziv8r7lmkm1ty9mqwxtk 2 0X00XXXX 2992-B1 Prime Therapeutics LLC 03/16
Specialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > December 2015 Specialty Pipeline Update New Drug Information Alecensa (alectinib): The Food and Drug Administration (FDA) approved Genentech s orally administered ALK
More informationSpecialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > September 2015 Specialty Pipeline Update New Drug Information Xuriden (uridine triacetate): The Food and Drug Administration (FDA) approved Wellstat Therapeutics oral
More informationSpecialty Pipeline Update
Specialty Pipeline Update D Drug Insights > December 2016 New drug information Rubraca (rucaparib): The U.S. Food and Drug Administration (FDA) granted accelerated approval to Clovis Oncology, Inc. s Rubraca
More informationPRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES REAL PATIENT; ANN (ALIAS) 63 year old woman who smoked for 25 years, quit 15 years ago. Complained
More informationClinical Therapeutic Intelligence Report: 2015 Year in Review
Clinical Therapeutic Intelligence Report: 2015 Year in Review This issue highlights the many ground-breaking therapies approved by the U.S. Food and Drug Administration over the course of 2015. Highlights
More informationSession 169 L, Quantifying Excess Specialty Drug Risk. Moderator: Patrick Gallagher, FSA, FCAS. Presenters: Robert Bachler, FSA, FCAS, MAAA
Session 169 L, Quantifying Excess Specialty Drug Risk Moderator: Patrick Gallagher, FSA, FCAS Presenters: Patrick Gallagher, FSA, FCAS Robert Bachler, FSA, FCAS, MAAA SOA Antitrust Disclaimer SOA Presentation
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationNICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017
NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationMedicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
More informationNew Drug and Therapeutic Biologic Approvals in 2015
New Drug and Therapeutic Biologic Approvals in 2015* Product Company Indication/Use Received** Approved Addyi Sprout Pharmaceuticals treatment of premenopausal women 10/27/2009 8/18/2015 flibanserin Raleigh,
More informationCriteria for Medical Benefit Drugs Requiring Clinical Review
Note: Authorization of a service based on the clinical information provided does not guarantee payment. The claim must be properly submitted and the member must be eligible on the date of service for the
More informationCriteria for Medical Benefit Drugs Requiring Clinical Review
Note: Authorization of a service based on the clinical information provided does not guarantee payment. The claim must be properly submitted and the member must be eligible on the date of service for the
More informationNew Cancer Drug Update 2015/2016. Teresa Knoop, MSN, RN, AOCN Vanderbilt-Ingram Cancer Center Nashville, TN
New Cancer Drug Update 2015/2016 Teresa Knoop, MSN, RN, AOCN Vanderbilt-Ingram Cancer Center Nashville, TN Disclosures No conflicts to disclose Objectives Identify new drugs that were FDA approved for
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationCompassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018
Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Het CBG kan in schrijnende gevallen toestemming verlenen voor het in de handel brengen van een geneesmiddel
More informationPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
More informationDrug Class Review Monograph GPI Class 12 Antivirals
Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,
More informationHepatitis C Virus Management
Hepatitis C Virus Management FDA-Approved Medications Hepatitis C is caused by a virus and results in liver inflammation, which can lead to advanced liver disease and/or liver cancer. An estimated 3 to
More informationPremera Blue Cross Medicare Advantage Plans Pharmacy Policy Updates
Premera Blue Cross Medicare Advantage Plans Pharmacy Policy Updates Most Part D-eligible drugs and drug policies are not effective and administered until Centers for Medicare and Medicaid Services approval
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationGoals & Objectives. Disclosure. Abbreviations. New and Emerging Chemotherapies 3/2/ Author has nothing to disclose
Goals & Objectives New and Emerging Chemotherapies Luis Hernandez PGY-1 Pharmacy Resident University of Miami Hospital www.fshp.org Distinguish key differences between new oral and parenteral chemotherapies
More informationNICE-approved drugs for specialities which fall outside of the services currently provided by the Trust
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir
More informationDirectorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationLUNCH AND LEARN. May 13, 2016
LUNCH AND LEARN New Drugs 2015 Part 2 May 13, 2016 Featured Speaker: Mary Lynn Moody, BSPharm Director, Business Development Drug Information Group Clinical Associate Professor University of Illinois at
More informationANDROID. Products Affected ANDROID. Prior Authorization Criteria HEALTH CHOICE EXCHANGE Effective Date: 12/01/2016
Prior Authorization HEALTH CHOICE EXCHANGE Effective Date: 12/01/2016 ANDROID ANDROID Supporting statement of diagnosis from the physician. Other 1 BLINCYTO BLINCYTO Known hypersensitivity to blinatumomab
More informationBLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125554/S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL Bristol-Myers
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationVectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
More information04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationAnticipated Launches Q Q2 2019
Anticipated Launches Q1 2019 Q2 2019 Disease Prevalence Multiple Sclerosis (MS) Mayzent (siponimod) oral Novartis secondary progressive multiple sclerosis (SPMS) Pending U.S. Food Drug (FDA) 03/25/2019
More informationLUNCH AND LEARN. April 8, 2016
LUNCH AND LEARN New Drugs 2015 Part 1 April 8, 2016 Featured Speaker: Mary Lynn Moody, BSPharm Director, Business Development Drug Information Group Clinical Associate Professor University of Illinois
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 28 th Prioritization 3 rd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationNew Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications
Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced
More information4/4/2016. Objectives Pharmacist. Objectives Technicians. WSPA New Drugs New Laws 2016 Seattle, WA Disclosure: No Conflicts of Interest
New Drug Update Terri L. Levien, Pharm.D. Clinical Professor WSU College of Pharmacy Spokane, Washington Levient@wsu.edu pharmacy.druginfo@wsu.edu WSU Drug Information Center: (509) 358 7662 WSPA New Drugs
More informationPharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C
Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C Effective: July 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical
More informationNew Drug Update Disclosure. Learning Objectives 2/17/2016. Nothing to disclose.
New Drug Update 2016 Katie Boyd, Pharm.D., BCPS Assistant Professor of Pharmacy Practice McWhorter School of Pharmacy, Samford University Disclosure Nothing to disclose. Learning Objectives Name the major
More informationSpecialty Pipeline Update
Specialty Pipeline Update D Drug Insights > March New drug information Xermelo (telotristat etiprate): The U.S. Food and Drug Administration (FDA) granted approval of Lexicon s Xermelo tablets for the
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for
More informationCENTENE PHARMACY & THERAPEUTICS COMMITTEE THIRD QUARTER 2017 NEW DRUG ARRIVALS SUMMARY TABLE. Utilization Management Recommendation
RT 1,2, 3,5 Drug Name 1 Brigatinib (Alunbrig ) 1 Deutetrabenazine (Austedo ) 1 Cerliponase alfa (Brineura ) Review Reason FDA-Approved (s) Alunbrig is indicated patients with anaplastic lymphoma kinase
More informationintolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra*
What s New Medical Pharmaceutical Policy March 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated policy Remicade (infliximab), Inflectra (infliximab-dyyb)
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 27 th Prioritization 2 nd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationCLINICAL MEDICATION POLICY
CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More informationChanges from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
More informationCriteria for Indiana Medicaid Hepatitis C Agents
Prepared for State of Indiana by OptumRx EXECUTIVE SUMMARY Purpose: Promote prudent prescribing of Setting & Population: All members Type of Criteria: Increased Risk of ADE Non-Preferred Agent Appropriate
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationCancer Therapy Update in 2017
Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationDRUG TRIALS SNAPSHOTS. Milena Lolic, MD, MS Medical Officer Professional Affairs and Stakeholder Engagement CDER/FDA
DRUG TRIALS SNAPSHOTS Milena Lolic, MD, MS Medical Officer Professional Affairs and Stakeholder Engagement CDER/FDA 1 Presentation Outline FDASIA 907 Overview What are Drug Trials Snapshots? Where to find
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationOncology Grand Rounds Series:
Oncology Grand Rounds Series: Part 6 Lymphomas and Chronic Lymphocytic Leukemia CNE Information TARGET AUDIENCE This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationMedicare Part D 2016 Formulary Changes Desert Preferred Choice
Medicare Part D 2016 Formulary s Desert Preferred Choice Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationONCOLOGY DRUG UPDATE 3/31/2017 DISCLOSURES OBJECTIVES OUTLINE QUIZ DRUG PIPELINE. I do not have any conflicts of interest or disclosures to make
DISCLOSURES I do not have any conflicts of interest or disclosures to make ONCOLOGY DRUG UPDATE Mark Wagner, PharmD, BCOP April 8 th, 2017 2 OBJECTIVES Identify the new medications that were approved in
More informationTo register or to learn more please visit:
A Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers When Saturday, October 29, 2016 8:00 AM to 4:00 PM Where JW Marriott
More informationCancer Drug Pipeline Information for Patient Advocacy Groups. Breast Cancer. Route of Administration. Brand Name Generic Name Manufacturer Indication
Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the will be submitted to the pcodr program. The use of this information is solely intended for informational
More informationwellinformed APRIL 2016
wellinformed APRIL 2016 New FDA-Approved Drugs The following drug products were recently approved by the U.S. Food and Drug Administration (FDA): Zemplar Paricalcitol Parathyroid hormone Sernivo Betamethasone
More informationPharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C
Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C Effective: March 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical
More information2018 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1127-9 Program Prior Authorization/Notification Medication Sovaldi (sofosbuvir) P&T Approval Date 2/2014, 4/2014, 5/2014, 8/2014,
More informationNCCN Guidelines for B-Cell Lymphomas V Update Meeting 08/14/18
DIAG-1 Submission request from Adaptive Biotechnologies to add NGS as an additional option to PCR for assessing IGH and TCR gene rearrangements under Essential Diagnosis: (immunohistochemistry, flow cytometry,
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationTreatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Archived Medical Policy
Treatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More information03 May 2016 Page 1 of 5. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationMedicare Part D 2016 Formulary Changes Service To Senior and OC Preferred
Medicare Part D 2016 Formulary s Service To Senior and OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationDescription of Commitment
AbbVie U.S. Postmarketing s Table: Name of ANDROGEL (testosterone gel) CREON (pancrelipase) CREON (pancrelipase) / 022309 and 021015 20725 20725 125057/0 125057/114 Description of A randomized, double-blind,
More informationTreatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie )
Treatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO
More informationDrug Prior Authorization Form Opdivo (nivolumab)
This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required
More informationApplications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use
7 January 2016 EMA/6499/2016 Information Management Division Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use January 2016 This document lists
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 7 Last Review Date: June 22, 2017 Afinitor Description Afinitor and
More informationREFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets
More informationClinical Pharmacy Program Guidelines for Hepatitis C Agents ARIZONA. Preferred Agents: Mavyret (glecaprevir/pibrentasvir)
Clinical Pharmacy Program Guidelines for Hepatitis C Agents ARIZONA Program Medication Prior Authorization Hepatitis C Agents 1. State Mandated Criteria - LOD Preferred Agents: Mavyret (glecaprevir/pibrentasvir)
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Technivie GENERIC NAME Ombitasvir/paritaprevir/ritonavir MANUFACTURER AbbVie, Inc. DATE OF APPROVAL February 27, 2017 PRODUCT LAUNCH DATE Already available on the market REVIEW TYPE Review type
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationHepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More information